$CRDL

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule. The company plans to expand enrollment to up to 150 patients to strengthen the assessment of CardiolRx™'s efficacy in treating recurrent pericarditis. Topline results are now expected in mid-2027, with sufficient capital to fund the trial completion and a cash runway into Q1 2028.

Cardiol Therapeutics (CRDL) raised over $7M from warrant exercises, extending its cash runway to H1 2028. The funds will support its Phase III MAVERIC trial for recurrent pericarditis and regulatory preparations for CardiolRx™, its lead drug candidate.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) filed a US$150 million preliminary base shelf prospectus, allowing potential future offerings. The filing includes expanded program and expense disclosure following OSC staff review. The company is advancing CardiolRx™ for heart disease treatments and developing CRD-38 for inflammatory heart disease.

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

Andrew Peller (ADW.A) reached a 52-week high of $8.00 after completing a transaction with Fairfax. Algoma Central (ALC.TO) hit $25.25, reporting Q2 revenues of $258,273. Argo Graphene (C.ARGO) hit $1.15 after appointing a new CEO. Boralex (BLX) reached $37.24 following its acquisition by Brookfield. Bank of Montreal (BMO) hit $258.11 after selling Moneris. Other companies also hit 52-week highs with varying news.

The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.

Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.